Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
WXXWY
$10.61
$
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
Next Earnings
2026-02-25
Beta
0.474
Average Volume
Market Cap
Last Dividend
CIK
ISIN
US98260N1081
CUSIP
98260N108
CEO
Zhisheng Chen
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
12575
IPO Date
2017-12-18
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| WuXi Biologics Awarded EcoVadis Platinum Medal for Third Consecutive Year, Ranking Among Top 1% Globally | SHANGHAI, Feb. 8, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), announced it has been awarded a Platinum Medal by the EcoVadis Sustainability Rating, marking the third year the company has received the rating's highest level of recognition. EcoVadis is among the world's most trusted and comprehensive sustainability assessment platforms, evaluating companies' ESG performance through 21 criteria across four key areas — Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. | PRNewsWire | 2026-02-08 21:30:00 |
| WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody | SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific antibody, for the potential treatment of inflammatory bowel disease (IBD) and other autoimmune diseases. Under the agreement, Sinorda Biomedicine will leverage WuXi Biologics' extensive experience and manufacturing capabilities in biologics development and manufacturing to advance SND006's preclinical pharmacology studies and clinical supply, accelerating the Investigational New Drug (IND) application process. | PRNewsWire | 2026-01-28 21:39:00 |
| Short Interest in WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) Drops By 70.7% | WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY - Get Free Report) was the target of a large drop in short interest during the month of January. As of January 15th, there was short interest totaling 22,350 shares, a drop of 70.7% from the December 31st total of 76,332 shares. Based on an average trading volume of 122,474 | Defense World | 2026-01-28 03:11:29 |
| HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline | SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio's pipeline. Under the agreement, WuXi Biologics will provide integrated, end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation development, and GMP manufacturing. | PRNewsWire | 2026-01-26 02:00:00 |
| WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY) Sees Large Growth in Short Interest | WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY - Get Free Report) saw a significant growth in short interest in December. As of December 31st, there was short interest totaling 76,332 shares, a growth of 52.4% from the December 15th total of 50,075 shares. Based on an average trading volume of 107,942 shares, the short-interest ratio is presently | Defense World | 2026-01-16 01:19:01 |
| JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth | Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects 209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients Complex modalities are WuXi Biologics' core growth engine, with 2/3 of the new integrated projects comprising bispecific/multispecific antibodies and ADCs Bispecific/multispecific antibodies are WuXi Biologics' most exciting, fastest‑growing and highest‑margin engine. With 196 projects in the pipeline, this modality contributes nearly 20% of the company's revenue and delivers 120%+ YoY growth Scaling integrated CRDMO capabilities across the U.S. and Asia, while expanding the global network into the Middle East SAN FRANCISCO, Jan. 14, 2026 /PRNewswire/ -- On January 14, Dr. Chris Chen, CEO of WuXi Biologics, delivered a keynote at the 44th J.P. | PRNewsWire | 2026-01-14 23:00:00 |
| WuXi Biologics (Cayman) Inc. (WXXWY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | WuXi Biologics (Cayman) Inc. (WXXWY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Seeking Alpha | 2026-01-14 20:05:58 |
| WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic | WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 (DP5) and Drug Product Packaging Center (DPPC) – have received GMP certifications from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for commercial manufacturing of an ophthalmic biologic. WuXi Biologics delivers end-to-end manufacturing services for this ophthalmic biologic, covering both drug substance and drug product. | PRNewsWire | 2026-01-12 22:07:00 |
| WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing | SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of PatroLabTM, a state-of-the-art digital twin platform designed to transform bioprocess development and manufacturing. By combining advanced real-time process monitoring with Raman-based Process Analytical Technology (PAT) and predictive in-silico modeling, PatroLab™ enables real-time and smarter analytics, proactive control, and accelerated decision-making. | PRNewsWire | 2026-01-12 08:09:00 |
| WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement | WUXI, China, Jan. 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK) announced it has achieved ISO 20400 Sustainable Procurement certification, an internationally recognized standard that integrates sustainability principles into procurement practices and promotes transparency and responsibility across the supply chain. This recognition highlights WuXi Biologics' outstanding performance in sustainability and showcases the company's dedicated efforts in strengthening supply chain resilience. | PRNewsWire | 2026-01-04 22:57:00 |
| WuXi Biologics Recognized by Hong Kong ESG Reporting Awards 2025 for Outstanding ESG Disclosure | HONG KONG , Dec. 23, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) has once again raised the bar for sustainability commitment and transparency. The company has been honored by the Hong Kong ESG Reporting Awards (HERA) 2025 for Outstanding ESG Disclosure, marking a new milestone in its dedication to openness and accountability. | PRNewsWire | 2025-12-23 23:30:00 |
| WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security | SHANGHAI , Dec. 19, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) announced that it has been named to the CDP "A" lists for both Climate Change and Water Security for 2025, underscoring its leadership in environmental stewardship and transparent disclosure. Climate Change Leadership Being recognized with an "A" rating by CDP for Climate Change affirms WuXi Biologics' leadership in environmental performance. | PRNewsWire | 2025-12-19 04:30:00 |
| WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority | DOHA, Qatar , Dec. 2, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has signed a strategic Memorandum of Understanding (MoU) with the Qatar Free Zones Authority (QFZ) to extend WuXi Biologics' global network and capabilities to the Middle East. The strategic collaboration paves the way for the establishment of WuXi Biologics' first integrated CRDMO center in the Middle East. | PRNewsWire | 2025-12-02 03:46:00 |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|